[go: up one dir, main page]

EP1421203A4 - Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof - Google Patents

Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Info

Publication number
EP1421203A4
EP1421203A4 EP02747843A EP02747843A EP1421203A4 EP 1421203 A4 EP1421203 A4 EP 1421203A4 EP 02747843 A EP02747843 A EP 02747843A EP 02747843 A EP02747843 A EP 02747843A EP 1421203 A4 EP1421203 A4 EP 1421203A4
Authority
EP
European Patent Office
Prior art keywords
prophylactic
enzymatic
diagnostic
screening
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02747843A
Other languages
German (de)
French (fr)
Other versions
EP1421203A2 (en
Inventor
Jay M Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Enzymes LLC
Original Assignee
Diversa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diversa Corp filed Critical Diversa Corp
Publication of EP1421203A2 publication Critical patent/EP1421203A2/en
Publication of EP1421203A4 publication Critical patent/EP1421203A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02747843A 2001-05-17 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof Withdrawn EP1421203A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30038101P 2001-05-17 2001-05-17
US300381P 2001-05-17
US30090701P 2001-06-25 2001-06-25
US300907P 2001-06-25
PCT/US2002/015767 WO2002092780A2 (en) 2001-05-17 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Publications (2)

Publication Number Publication Date
EP1421203A2 EP1421203A2 (en) 2004-05-26
EP1421203A4 true EP1421203A4 (en) 2005-06-01

Family

ID=26971759

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02747843A Withdrawn EP1421203A4 (en) 2001-05-17 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Country Status (3)

Country Link
EP (1) EP1421203A4 (en)
JP (1) JP2004532038A (en)
WO (1) WO2002092780A2 (en)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
PT1691837E (en) 2003-12-10 2012-08-27 Medarex Inc Ip-10 antibodies and their uses
SI2418220T1 (en) 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
DK1781705T3 (en) 2004-06-21 2015-01-12 Squibb & Sons Llc Interferon-alpha receptor 1 antibodies and uses thereof
PL2161336T5 (en) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR20080032097A (en) 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 CD19 antibody and uses thereof
CN104356236B (en) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibody against programmed death ligand 1 (PD-L1)
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
PL1960434T3 (en) 2005-12-08 2012-12-31 Squibb & Sons Llc Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
EP2010569A4 (en) 2006-03-20 2009-09-09 Xoma Technology Ltd FOR GASTRIN SPECIFIC HUMAN ANTIBODIES, MATERIALS AND METHODS
KR20140033236A (en) 2006-08-04 2014-03-17 노바르티스 아게 Ephb3-specific antibody and uses thereof
EP2046834B9 (en) 2006-08-11 2013-04-10 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
AU2007285855B2 (en) 2006-08-18 2013-03-07 Novartis Ag PRLR-specific antibody and uses thereof
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
SI2486941T1 (en) 2006-10-02 2017-08-31 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
DK2068922T3 (en) 2006-10-19 2012-10-08 Csl Ltd Anti-IL-13Ralfa1 antibodies and their applications
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
AU2007334264A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
WO2009032845A2 (en) 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AR068767A1 (en) 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
ES2663077T3 (en) 2007-11-02 2018-04-11 Novartis Ag Molecules and methods of modulation of protein 6 related to the low density lipoprotein receptor (lrp6)
EP2650017A3 (en) 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
JP5504587B2 (en) * 2008-05-27 2014-05-28 東レ株式会社 Analysis chip
ES2643411T3 (en) 2008-08-05 2017-11-22 Novartis Ag Compositions and methods for antibodies directed to the complement protein C5
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
LT2403878T (en) 2009-03-05 2017-10-10 E. R. Squibb & Sons, L.L.C. Fully human antibodies specific to cadm1
SG10201401604VA (en) 2009-04-20 2014-08-28 Oxford Biotherapeutics Ltd Antibodies Specific To Cadherin-17
CA2758290C (en) 2009-04-27 2018-04-10 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
JP2012524524A (en) 2009-04-27 2012-10-18 ノバルティス アーゲー Composition of therapeutic antibodies specific for IL-12 receptor β1 subunit and methods of use
EP3156485B1 (en) * 2009-07-17 2018-09-12 Bioatla, LLC Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP5885664B2 (en) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド Screening method
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
EP2507265B1 (en) 2009-12-01 2016-05-11 Compugen Ltd. Antibody specific for heparanase splice variant T5 and its use.
EP3153521B1 (en) 2010-03-26 2019-09-04 Trustees of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
CA2804746C (en) 2010-07-16 2022-01-11 Jay M. Short Novel methods of protein evolution
CA2807616A1 (en) 2010-08-09 2012-02-16 Richard Markham Methods and compositions for preventing a condition
PL2606070T3 (en) 2010-08-20 2017-06-30 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
CA3182320A1 (en) 2010-09-23 2012-03-29 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012092323A1 (en) 2010-12-28 2012-07-05 Xoma Technology Ltd. Cell surface display using pdz domains
SG10201603034TA (en) 2011-04-15 2016-05-30 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
PL2714735T3 (en) 2011-06-03 2022-02-21 Xoma Technology Ltd. Antibodies specific for tgf-beta
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
MY177267A (en) 2011-06-28 2020-09-10 Berlin Chemie Ag Antibodies
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
PL2726099T3 (en) 2011-07-01 2018-12-31 Novartis Ag Method for treating metabolic disorders
BR112014013568A2 (en) 2011-12-05 2017-06-13 Novartis Ag epidermal growth factor 3 (her3) receptor antibodies directed to her3 domain ii
SG11201402783YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
BR112014018481A2 (en) 2012-02-01 2017-07-04 Compugen Ltd monoclonal or polyclonal antibody or antigen-binding fragment thereof, polynucleotide, monoclonal antibody, vector, hybridoma, antibody, hybridoma 5166-2 and / or 5166-9, antigen-binding antibody or fragment, pharmaceutical composition, antibody use or antibody binding fragment, method for treating cancer, method for diagnosing cancer in an individual, antibody, method, composition or use
CN104619722B (en) 2012-06-22 2022-10-04 达特茅斯大学理事会 Novel VISTA-IG constructs and use of VISTA-IG for treatment of autoimmune, allergic and inflammatory diseases
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
EP2892558B1 (en) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
AU2013355414B2 (en) 2012-12-05 2017-02-02 Novartis Ag Compositions and methods for antibodies targeting EPO
KR20150095684A (en) 2012-12-18 2015-08-21 노파르티스 아게 Compositions and methods that utilize a peptide tag that binds to hyaluronan
ES2667333T3 (en) 2012-12-28 2018-05-10 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
MA38322B1 (en) 2013-02-08 2018-09-28 Novartis Ag Anti-il-17a antibodies and their use in the treatment of autoimmune and inflammatory disorders
EP3611189A1 (en) 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
SI3712174T1 (en) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv VISTA antibodies and particles
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
TW201622746A (en) 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture
PT3151921T (en) 2014-06-06 2019-11-21 Bristol Myers Squibb Co ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEIVER AND USES OF THE SAME
JP6997619B2 (en) 2014-06-11 2022-01-17 キャシー・エイ・グリーン Use of VISTA agonists and VISTA antagonists for suppression or enhancement of humoral immunity
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
DK3177642T3 (en) 2014-08-07 2022-02-21 Novartis Ag ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USING IT
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
DK3221363T3 (en) 2014-11-21 2020-08-10 Bristol Myers Squibb Co ANTIBODIES TO CD73 AND USES THEREOF
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
DK3303396T5 (en) 2015-05-29 2024-10-07 Bristol Myers Squibb Co ANTIBODIES AGAINST OX40 AND USES THEREOF
CA2982237A1 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
JOP20200312A1 (en) 2015-06-26 2017-06-16 Novartis Ag Factor xi antibodies and methods of use
WO2017021893A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
MX2018003038A (en) 2015-09-09 2018-04-11 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies.
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
CN108738324B (en) 2015-11-19 2022-06-21 百时美施贵宝公司 Anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and uses thereof
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
CN109069626A (en) 2016-02-12 2018-12-21 詹森药业有限公司 Anti-VISTA(B7H5) antibody
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
EP3442579A4 (en) 2016-04-15 2019-12-18 Immunext Inc. ANTI-HUMAN ANTI-VISTA ANTIBODIES AND USES THEREOF
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
TW201802121A (en) 2016-05-25 2018-01-16 諾華公司 Reversal binding agent against factor XI/XIa antibody and use thereof
KR102492057B1 (en) 2016-06-15 2023-01-26 노파르티스 아게 Methods of treating diseases using inhibitors of bone morphogenetic protein 6 (BMP6)
BR112019000431A2 (en) 2016-07-14 2019-07-09 Bristol-Myers Squibb Company antibodies against tim3 and their uses
WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
AU2017353939B2 (en) 2016-11-07 2025-01-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
CN110325550B (en) 2016-12-23 2024-03-08 诺华股份有限公司 Factor XI Antibodies and How to Use
AU2017386682A1 (en) 2016-12-28 2019-07-25 Invvax, Inc. Influenza vaccines
ES3035810T3 (en) 2017-02-08 2025-09-09 Novartis Ag Fgf21 mimetic antibodies and uses thereof
LT3600415T (en) 2017-03-24 2025-12-29 Novartis Ag Antibody against activin receptor type ii receptor for use in treating heart failure
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN111315774B (en) 2017-06-27 2023-12-22 纽洛可科学有限公司 Anti-FAM19A5 antibodies and their uses
TW201906865A (en) 2017-06-28 2019-02-16 瑞士商諾華公司 Method of preventing and treating urinary incontinence
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019102353A1 (en) 2017-11-22 2019-05-31 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
EP3746477A1 (en) 2018-02-02 2020-12-09 Bio-Techne Corporation Compounds that modulate the interaction of vista and vsig3 and methods of making and using
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
TWI853807B (en) 2018-03-28 2024-09-01 美商必治妥美雅史谷比公司 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
CN112119091B (en) 2018-05-10 2025-01-03 纽洛可科学有限公司 Antibodies against sequence similarity family 19 member A5 and methods of using the same
TWI869346B (en) 2018-05-30 2025-01-11 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
US20220025070A1 (en) 2018-12-18 2022-01-27 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
JP7649744B2 (en) 2018-12-26 2025-03-21 イムチェック セラピューティクス エスエーエス BTN3A BINDING PROTEINS AND USES THEREOF
CN113195533B (en) 2019-01-02 2024-04-26 纽洛可科学有限公司 Antibodies against sequence similarity family 19 member A5 and methods of using the same
AU2020210635B2 (en) 2019-01-22 2024-12-12 Bristol Myers Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
CN114502590A (en) 2019-09-18 2022-05-13 诺华股份有限公司 ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies
MX2023000547A (en) 2020-07-16 2023-02-13 Novartis Ag ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES.
EP4189084A1 (en) * 2020-07-27 2023-06-07 Wisconsin Alumni Research Foundation Methods of making unbiased phage libraries
JP2024514530A (en) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Antibodies against truncated CDCP1 and uses thereof
WO2023217743A1 (en) 2022-05-10 2023-11-16 Imcheck Therapeutics Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015581A1 (en) * 1990-04-05 1991-10-17 Roberto Crea Walk-through mutagenesis
WO1998027230A1 (en) * 1996-12-18 1998-06-25 Maxygen, Inc. Methods and compositions for polypeptide engineering
WO2000018906A2 (en) * 1998-09-29 2000-04-06 Maxygen, Inc. Shuffling of codon altered genes
WO2000053744A2 (en) * 1999-03-09 2000-09-14 Diversa Corporation End selection in directed evolution

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238884B1 (en) * 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015581A1 (en) * 1990-04-05 1991-10-17 Roberto Crea Walk-through mutagenesis
WO1998027230A1 (en) * 1996-12-18 1998-06-25 Maxygen, Inc. Methods and compositions for polypeptide engineering
WO2000018906A2 (en) * 1998-09-29 2000-04-06 Maxygen, Inc. Shuffling of codon altered genes
WO2000053744A2 (en) * 1999-03-09 2000-09-14 Diversa Corporation End selection in directed evolution

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HORWITZ B H ET AL: "SATURATION MUTAGENESIS USING MIXED OLIGONUCLEOTIDES AND M13 TEMPLATES CONTAINING URACIL", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 185, 1990, pages 599 - 611, XP000993477, ISSN: 0076-6879 *
SCHULTZ S ET AL: "Site-saturation studies of beta-lactamase: production and characterization of mutant beta-lactamases with all possible amino acid substitutions at residue 71", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 83, no. 6, March 1986 (1986-03-01), pages 1588 - 1592, XP002147196, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002092780A2 (en) 2002-11-21
JP2004532038A (en) 2004-10-21
WO2002092780A3 (en) 2004-03-25
EP1421203A2 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
EP1421203A4 (en) Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
IL172871A0 (en) Rg1 antibodies and uses thereof
AU2003222142A1 (en) Micro/nano-embossing process and useful applications thereof
EP1247815A3 (en) Modified oligonucleotides and uses thereof
MXPA03007197A (en) Therapeutic binding molecules.
EP1583428A4 (en) Dairy protein process and applications thereof
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2001275990A1 (en) 16816 and 16839, novel human phospholipase c molecules and uses therefor
AUPR535101A0 (en) Novel therapeutic molecules
AU2002327945A1 (en) Human delta-n p73 molecules and uses thereof
AU2002334781A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
GB0414424D0 (en) Polymer and process for producing polyer
AU2002309646A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
GB0115780D0 (en) Therapeutic molecules and uses thereof
AU2002953223A0 (en) Novel therapeutic molecules and uses thereof
WO2003023002A9 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002303232A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002337248A1 (en) Nucleic acids coding for novel fbox proteins, their diagnostic and therapeutic uses
AU2002302191A1 (en) Socs-5 molecules, screening therefore and therapeutic uses thereof
AU2002322404A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002254163A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2001294181A1 (en) Novel protein, process for producing the same and use thereof
AU2002356472A1 (en) Dairy process and product
AUPR713201A0 (en) Novel therapeutic molecules and uses therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050415

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12N 15/66 B

Ipc: 7C 12N 15/10 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060912